SCHEMBL1310474

SCHEMBL1310474

CCOC(=O)C1(CC)CCN(C(=O)O)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.45
KMT2A Q03164 9/20 0.45
ALDH1A1 P00352 9/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 1/20 0.41
POLB P06746 2/20 0.41
RECQL P46063 1/20 0.40
MAPK1 P28482 1/20 0.40
SLC22A1 O15245 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4556747 0.87 MEN1 (0.43) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL28017587 0.84 LMNA (0.44) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL17611774 0.84 MEN1 (0.42) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL17611768 0.83 MEN1 (0.42) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL12950188 0.82 OPRM1 (0.53) MEN1KMT2AALDH1A1LMNARAB9A
SCHEMBL4551724 0.82 OPRM1 (0.42) MEN1KMT2AALDH1A1POLBSLC22A1
SCHEMBL1447297 0.82 KMT2A (0.46) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL2295307 0.81 ALDH1A1 (0.42) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL3611228 0.81 OPRM1 (0.41) MEN1KMT2AALDH1A1LMNASLC22A1
SCHEMBL17611728 0.81 MEN1 (0.47) MEN1KMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877968-B2 Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-11-04 US disclosed
EP-2352728-B1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RES & DEV (FR) 2014-05-21 EP disclosed
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US disclosed
EP-2352728-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS Galderma Research & Development (FR) 2011-08-10 EP disclosed
WO-2010052255-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS MC1R, MC5R, MC3R MEN1 274/4885KMT2A 2487/4885ALDH1A1 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.